WaveMan
WaveMan · Company
KPTI · Karyopharm Therapeutics Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

KPTI Karyopharm Therapeutics (KPTI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001503802
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
64
13F, latest reported quarter

What the filings say about KPTI

Insiders, 180 days
-$38.2K net sold
6 sellers · 0% of sales under a 10b5-1 plan

Karyopharm Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Karyopharm Therapeutics Inc. insiders sold a net $38.2K of stock across 159 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Abate Kristin
Chief Accounting Officer
SELL
2026-10-19 SECtraded 2026-10-16
4,788
$1.6K
+34.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Oct 1, 2026.
  • The trade is 25.7% of the 18,616 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Abate Kristin sold about $1.6K of KPTI on Oct 16, 2026; 64 funds added in the latest 13F quarter.
Abate Kristin
Chief Accounting Officer
SELL
2026-10-02 SECtraded 2026-10-01
378
$450
-28.2%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 1, 2026.
  • The trade is 1.6% of the 23,404 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Abate Kristin sold about $450 of KPTI on Oct 1, 2026; 64 funds added in the latest 13F quarter.
Abate Kristin
Chief Accounting Officer
SELL
2026-09-02 SECtraded 2026-09-01
19
$38
-72.8%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on May 14, 2026.
  • The trade is 0.1% of the 23,782 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Abate Kristin sold about $38 of KPTI on Sep 1, 2026; 64 funds added in the latest 13F quarter.
Poulton Stuart
EVP, Chief Development Officer
SELL
2026-07-30 SECtraded 2026-07-28
189
$1.3K
-74.9%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on May 14, 2026.
  • The trade is 0.2% of the 94,632 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Development Officer Poulton Stuart sold about $1.3K of KPTI on Jul 28, 2026; 64 funds added in the latest 13F quarter.
Poulton Stuart
EVP, Chief Development Officer
SELL
2026-05-15 SECtraded 2026-05-14
403
$3.8K
-93.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Mar 2, 2026.
  • The trade is 0.4% of the 94,821 shares held after it.
  • 5 other insiders sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Development Officer Poulton Stuart sold about $3.8K of KPTI on May 14, 2026; 5 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
159 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 154 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$38.2K over 180 days
-$2.1K over 90 days
more than 58% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
64 funds bought in last quarter
more than 53% of Pharma & Biotech
Revenue
+0.6% year over year
below 52% of Pharma & Biotech
Margin
-134.2% net margin
below 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
42.0% of the float short (float per yahoo 2026-10-27) · 4.8 days to cover · settled 2026-10-15
more than 99% of Pharma & Biotech
What changed in the last 30 days
Oct 19Chief Accounting Officer Abate Kristin sold $2.1K (2 trades, Oct 1 to Oct 16)

Watch KPTI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-92.2%12M
-95%-39%+17%+72%2025-102025-122026-022026-042026-062026-082026-10 2026-03-02 · Paulson Richard A. sold $116.3K2026-03-02 · Poulton Stuart sold $48.0K2026-03-02 · Rangwala Reshma sold $47.7K2026-03-02 · Cheng Sohanya Roshan sold $43.3K2026-03-02 · Mano Michael sold $33.2K2026-05-14 · Paulson Richard A. sold $20.9K2026-02-03 · Macomber Lori sold $10.2K2026-03-02 · Abate Kristin sold $5.3K2026-04-21 · Rangwala Reshma sold $4.0K2026-05-14 · Rangwala Reshma sold $3.9K2026-05-14 · Poulton Stuart sold $3.8K2026-02-17 · Poulton Stuart sold $3.3K2026-05-14 · Cheng Sohanya Roshan sold $3.1K2026-05-14 · Mano Michael sold $2.5K2026-10-16 · Abate Kristin sold $1.6K2026-01-21 · Abate Kristin sold $1.6K2026-07-28 · Poulton Stuart sold $1.3K2026-05-14 · Abate Kristin sold $5042026-10-01 · Abate Kristin sold $4502026-01-28 · Abate Kristin sold $3522026-09-01 · Abate Kristin sold $38
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KPTI: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
1,917,354 sh
$18.7M
ADAGE CAPITAL PARTNERS GP, L.L.C.
1,521,322 sh
$14.9M
ACORN CAPITAL ADVISORS, LLC
1,518,113 sh
$14.8M
GOLDMAN SACHS GROUP INC
1,424,658 sh
$13.9M
BlackRock, Inc.
1,418,799 sh
$13.9M

Congress trades in KPTI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KPTI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

KPTI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$487.3K position · as of 2026-06-30
0.5%
Ultra-Small Company Market Fund
$214.9K position · as of 2026-06-30
0.1%
T. Rowe Price Health Care ETF
$24.1K position · as of 2026-06-30
0.1%
Nomura Healthcare Fund
$325.7K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$654.0K position · as of 2026-06-30
0.0%
T. Rowe Price Small-Cap Value Fund, Inc.
$4.3M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
37 registered trials, 8 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
5
Phase 1
0 active
18
Phase 2
4 active
4
Phase 3
2 active
1
Not applicable
0 active
9
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr Kauffman
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.3M
$2.1M
$1.7M
-86%
n/a
2024
$2.1M
$1.7M
$1.1M
-80%
n/a
2023
$2.6M
$35.7K
$1.2M
-75%
n/a
2022
$6.9M
$1.6M
$2.9M
-47%
n/a
2020
$3.9M
$1.8M
$3.0M
-19%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $38.2K sold by insiders over 180 days, 64 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KPTI financials

Revenue growth
+0.6%
XBRL, annual
Net margin
-134.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$146.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-153.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$65.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.39x
TTM operating cash flow over long-term debt only, 2021-12-31 (54 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-207.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$125.2M
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
FCF yield
-597.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$146.1M$145.2M$146.0M$157.1M
Operating income-$90.7M-$119.4M-$129.5M-$142.2M
Net income-$196.0M-$76.4M-$143.1M-$165.3M
EPS (diluted)-17.93-14.00-18.79-2.02
Operating cash flow-$75.4M-$127.5M-$92.7M-$149.6M
Cash$60.5M$62.5M$52.2M$135.2M
SEC XBRL, fiscal years, as known on 2026-10-28

KPTI Stock Sonar score 5/7 axes

Find similar shapesCompare

KPTI ranks highest on financial health (61st percentile) and growth (48th), and lowest on risk and compliance (14th), among Pharma & Biotech peers.

HealthGrowthInsidersInstitutionsRisk
Financial health
61
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.39x · 61 pct, sector of 371
Growth
48
Inputs
  • Revenue growth, YoY+0.6% · 48 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
28
Inputs
  • Net Form 4 buying (codes P and S), 180d-$38K · 56 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
36
Inputs
  • Funds adding, latest quarter64 · 53 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$100K · 20 pct, sector of 133
Risk and compliance
14
Inputs
  • Short interest, % of float+42.0% · 1 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+16.4% · 26 pct, sector of 511
2 not measured: Profitability, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; pre-tax loss, no effective tax rate to apply
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KPTI filings, in plain words

Are Karyopharm Therapeutics insiders buying or selling KPTI?

In the 180 days to 2026-10-28, Karyopharm Therapeutics insiders were net sellers, a net $38.2K across purchases and sales reported on Form 4, by 6 sellers.

Read the full summary

In the 180 days to 2026-10-28, Karyopharm Therapeutics insiders were net sellers of KPTI, a net $38.2K across purchases and sales reported on Form 4 by 6 sellers. None of the 10 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies